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Abstract 39 
Objective: Apolipoprotein D (ApoD) is an atypical apolipoprotein with an 40 
incompletely understood function in the regulation of triglyceride and glucose 41 
metabolism. We have demonstrated that elevated ApoD production in mice results in 42 
improved postprandial triglyceride clearance. This work studies the role of ApoD 43 
deficiency in the regulation of triglyceride and glucose metabolism and its 44 
dependence on aging. 45 
Methods/materials: We used ApoD knockout (ApoD-KO) mice of 3 and 21 months 46 
of age. Body weight and food intake were measured. Hepatic histology, triglyceride 47 
content, lipoprotein lipase levels (LPL) and plasma metabolites were studied. 48 
Phenotypic characterization of glucose metabolism was performed using glucose 49 
tolerance test. Beta-cell mass, islet volume and islet number were analyzed by 50 
histomorphometry. 51 
Results: ApoD deficiency results in non-fasting hypertriglyceridemia in young 52 
(p=0,01) and aged mice (p=0,002). In young ApoD-KO mice, hypertriglyceridemia 53 
was associated with 30-50% increased food intake in non-fasting and fasting 54 
conditions respectively, without changes in body weight. In addition, LPL levels were 55 
reduced by 35% in adipose tissue (p=0,006). In aged ApoD-KO mice, 56 
hypertriglyceridemia was not associated with changes in food intake or body weight, 57 
whereas hepatic triglyceride levels were reduced by 35% (p=0,02). Furthermore, 58 
non-fasting plasma insulin levels were elevated by 2-fold in young (p=0,016) and 59 
aged (p=0,004) ApoD-KO mice, without changes in blood glucose levels, glucose 60 
tolerance, beta cell mass or islet number. 61 
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Conclusions: These findings underscore the importance of ApoD in the regulation of 62 
plasma insulin levels and triglyceride metabolism, suggesting that ApoD plays an 63 
important role in the pathogenesis of dyslipidemia.  64 
 65 
Key words: Dyslipidemia, lipoprotein lipase, insulin resistance, beta-cell function, 66 
lipocalins. 67 
Abbreviations: ApoD, Apolipoprotein D; HDL, high density lipoprotein; LDL, low 68 
density lipoprotein; VLDL, very low density lipoprotein; WT, wild type mice; ApoD-KO, 69 
Apolipoprotein D knockout mouse; TG, triglycerides; CHL, total cholesterol; LCN2, 70 
Lipocalin-2; LPL, Lipoprotein lipase; RBP4, Retinol-Binding Protein 4. 71 
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Introduction 73 
Apolipoprotein D (ApoD) is a Lipocalin widely expressed in mammalian tissues and 74 
known to bind a series of hydrophobic ligands in vitro with high affinity 75 
(pregnenolone, progesterone and arachidonic acid) [1-3] as well as cholesterol with 76 
very low affinity [4]. The expression of ApoD is prominent in the nervous system, 77 
particularly upon aging or induced damage. We have shown that it exerts protective 78 
roles in both situations: by controlling the levels of brain peroxidated lipids in a model 79 
of accelerated aging by oxidative insult [5], or by controlling the extent and duration 80 
of inflammatory processes after peripheral nerve injury [6], influencing this way the 81 
rate of nerve regeneration. 82 
Curiously, ApoD was simultaneously discovered in the human breast cyst fluid and 83 
as an apolipoprotein present in high-density lipoproteins (HDL) and to a lesser extent 84 
in very low-density lipoproteins (VLDL) [7,8]. ApoD is an atypical apolipoprotein, 85 
unrelated to other apolipoproteins in both structure and evolutionary origins [9]. 86 
Because ApoD is mainly located in HDL, it was soon proposed to have a role in lipid 87 
homeostasis [10]. 88 
The Drosophila genome contains two Lipocalin homologues of vertebrate ApoD, Glial 89 
Lazarillo (GLaz) and Neural Lazarillo (NLaz), mainly expressed in glia and neurons 90 
respectively [11,12]. Genetic ablation of GLaz or NLaz reduces total triglyceride 91 
content and resistance to starvation  in young flies [11,12], while aging is 92 
accompanied by neutral fats accumulation in NLaz deficient flies  [13]. In contrast, 93 
overexpression of NLaz increases total triglyceride content and resistance to 94 
starvation [11]. In addition to its role in the regulation of lipid metabolism, NLaz 95 
mutants exhibit low glucose levels, whereas flies overexpressing NLaz show 96 
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elevated glucose levels [11]. Taken together, these studies illustrate that the 97 
Drosophila ApoD homologues GLaz and NLaz play a role in the regulation of lipid 98 
and glucose metabolism, besides their roles in nervous system physiology. 99 
To gain insights into the role of ApoD in the regulation of lipid metabolism in a 100 
vertebrate model organism, we have previously used a gain-of-function approach to 101 
overexpress ApoD in mouse. Elevated ApoD production in the liver of young mice 102 
results in enhanced lipoprotein lipase (LPL) activity and improved postprandial 103 
triglyceride clearance, whereas VLDL-triglyceride production remained unchanged 104 
[14]. However, brain overexpression of human ApoD in middle-aged mice results in 105 
hepatic steatosis, despite normal lipid concentration in circulation, glucose 106 
intolerance and insulin resistance [15]. Finally, epidemiological studies in humans 107 
associate ApoD genetic variants with elevated plasma triglyceride levels [16,17], and 108 
the TaqI polymorphism of the APOD gene is associated with the development of 109 
obesity, insulin resistance, hyperinsulinemia and type 2 diabetes [18,19]. 110 
Thus, the precise role of mammalian ApoD in the regulation of lipid metabolism has 111 
only recently started to be addressed and to fully understand the role of ApoD in 112 
triglyceride metabolism, an analysis of the loss-of-function mouse model is required. 113 
In this study, we hypothesized that a loss of ApoD would increase plasma triglyceride 114 
levels, contributing to the pathogenesis of dyslipidemia. To address this hypothesis, 115 
we evaluated the impact of losing ApoD on triglyceride metabolism in young and 116 
aged ApoD-deficient mice (ApoD-KO). Here we show that genetic ablation of ApoD 117 
results in hypertriglyceridemia and hyperinsulinemia in non-fasting conditions. These 118 
findings underscore the importance of ApoD in the regulation of triglyceride 119 
metabolism and in insulin-dependent processes. 120 
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Methods 121 
Ethical approval 122 
Experimental procedures were approved by the Animal Care and Use Committee of 123 
the University of Valladolid in accordance with the Guidelines for the Care and Use of 124 
Mammals in Research (European Commission Directive 86/609/CEE and Spanish 125 
Royal Decree 1201/2005). 126 
Experimental Animals 127 
WT and ApoD-KO mice were bred at the animal facility of the University of Valladolid, 128 
Spain. ApoD-KO mice were generated and genotyped as previously described [5]. 129 
Mice were fed standard rodent chow and water ad libitum in ventilation-controlled 130 
cages in a 12 h-light/dark cycle. The experimental cohorts used in this study were 131 
males of the F1 generation of homozygous crosses. The parental generation was 132 
composed of ApoD-/- and ApoD+/+ littermates from heterozygous crosses of the 133 
ApoD-KO line in C57BL/6 background. This strategy avoids the potential maternal 134 
effects of ApoD and generates wild-type and ApoD-KO cohorts with a homogeneous 135 
genetic background. Two independent cohorts were used for the collection of tissues 136 
at two ages: 3 months (n=10/genotype) and 21 months old (n=11/genotype). 137 
Plasma Biochemistry 138 
Blood samples were obtained from mice under fasting conditions (16 hours) or under 139 
non-fasting conditions (animals had free access to food pellets ad libitum for 48 h 140 
after the fasting period). This paradigm compares fasting versus non-fasting 141 
conditions, since the exact timing of food intake with respect to sample collection is 142 
not determined. Blood was collected from the tail vein into capillary tubes precoated 143 
with potassium-EDTA (Sarstedt, Nümbrecht, Germany) for the preparation of plasma. 144 
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Blood glucose levels were determined using a Glucometer Xceed (Abbott Diabetes 145 
Care Ldt., Oxon, UK). Plasma triglycerides and cholesterol levels were determined 146 
using the Wako triglyceride and cholesterol reagents (Wako Chemicals GmbH, 147 
Neuss, Germany). Plasma insulin levels were measured using ultrasensitive mouse 148 
ELISA (ALPCO Diagnostics, NH, USA). 149 
Food intake 150 
For food intake determination, ApoD-KO and WT mice were separated in individual 151 
cages (n=7-11 mice per genotype). After the 16 h fasting period, food pellets (50 g) 152 
were added to each cage, and food intake of each mouse was estimated from the 153 
difference in remaining food weight at 24 and 48 h. These weights were averaged to 154 
provide an estimate of the mean food intake of each genotype in the 48 h period 155 
following fasting. 156 
Glucose tolerance test and insulin sensitivity index 157 
Mice were fasted for 16 hours and injected intraperitoneally with glucose at 2g/Kg of 158 
body weight. Blood glucose levels were determined and plotted as a function of time. 159 
Insulin sensitivity index (ISI) was calculated using the formula ISI= 2/[(INSXGLU)+1], 160 
where INS is fasting plasma insulin levels and GLU is fasting blood glucose levels 161 
with values converted to pmol/L and mmol/L respectively [20]. 162 
Hepatic triglyceride determination and liver histology 163 
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Hepatic triglyceride determination was performed as previously described [14]. For 164 
liver histology, standard paraffin and cryostat sections were performed after fixation 165 
in 4% paraformaldehyde as previously described [6]. Oil-red O staining was 166 
performed on 10 µm cryostat sections using isopropanol as diluent. Hematoxilin-167 
Eosin staining was performed on 3 µm paraffin sections following standard 168 
procedures [6].  169 
Determination of islet mass and islet histomorphometry 170 
Pancreata were excised, fixed, sectioned, stained with insulin, and quantitative islet 171 
histomorphometry was performed as previously described [21]. 172 
Immunoblot analysis 173 
To determine the effect of ApoD deficiency on LPL protein expression, epididymal fat 174 
tissue was collected from experimental and control mice. Cell extracts were obtained 175 
in lysis buffer (Cell Lysis Buffer, Cell Signaling, Beverly, MA) supplemented with 176 
protease inhibitors (Protease Inhibitor Cocktail Sigma, St. Louis, MO). Solubilized 177 
proteins (20 µg/lane) were separated by SDS-PAGE and electrotransferred onto 178 
polyvinylidene difluoride membranes for conventional immunoblotting. After probing 179 
with LPL-specific antibody (1:1000, Santa Cruz Biotechnology Inc., Heidelberg, 180 
Germany) the membranes were stripped and reprobed with antibody against -actin 181 
(1:5000, Sigma). Chemiluminiscence signals (ECL Plus detection system, Amersham 182 
Biosciences, Piscataway, NJ, USA) were detected in the linear range for 183 
quantification purposes. 184 
Statistical analysis 185 
Statistical analyses of data were performed by Student-t test and by analysis of 186 
variance (ANOVA). Data were expressed as mean ± SD. P values <0.05 were 187 
considered significant.188 
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Results 189 
Effect of ApoD deficiency on triglyceride metabolism in mice 190 
We reported that elevated ApoD production resulted in significant reduction in 191 
plasma TG levels in mice [14]. Here, we determined the impact of ApoD on 192 
triglyceride metabolism in the ApoD knockout mice (ApoD-KO). When compared to 193 
control, non-fasting ApoD-KO mice exhibited significantly increased TG levels at 3 194 
and 21 months of age (Fig. 1A). In contrast, fasting plasma TG levels remained 195 
unchanged (Fig. 1A). Whereas ApoD deficiency reduced plasma cholesterol levels in 196 
ApoD-KO mice at 3 months of age, this reduction was not observed at 21 months of 197 
age (Fig 1B). In addition, ApoD deficiency resulted in a significantly increased food 198 
intake at 3 months of age (Fig. 1C) without differences in body weight (Fig. 1D). 199 
However, food intake and body weight at 21 months remained unchanged (Fig. 1C-200 
D). 201 
To investigate the potential effect of ApoD deficiency on hepatic fat metabolism we 202 
determined hepatic triglyceride content. When compared with control mice, ApoD-KO 203 
mice exhibited a trend (16% reduction) in hepatic TG content at 3 months of age 204 
(however differences did not reach statistical significance, data not shown). In 205 
contrast, hepatic TG content was significantly reduced by 35% in ApoD-KO mice at 206 
21 months of age compared to control mice (Fig. 2A). To confirm these findings, liver 207 
tissues from both ApoD-KO and control groups were stained with Oil Red O. 208 
Histological examination of liver sections revealed significant differences in hepatic 209 
triglyceride content in ApoD-KO and control mice at 21 months of age (Fig. 2B). 210 
To investigate the mechanism by which ApoD deficiency is associated with non-211 
fasting hypertriglyceridemia we analyzed the expression level of lipoprotein lipase 212 
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(LPL), a key enzyme in the hydrolysis and clearance of TG-rich particles, in 213 
peripheral tissues of young mice. As shown in Fig.3, LPL levels in adipose tissue 214 
from young mice were reduced by 30-40% in ApoD-KO mice compared to WT control 215 
animals. These results shed light on the mechanism by which ApoD deficiency is 216 
associated with non-fasting hypertriglyceridemia and spur the hypothesis that ApoD 217 
deficiency reduces TG clearance through decreased LPL activity.  218 
Effect of ApoD deficiency on glucose metabolism in mice 219 
Elevated serum triglycerides are often associated with insulin resistance in rodents 220 
and humans [22]. To investigate the effect of ApoD deficiency on glucose metabolism 221 
we determined blood glucose and insulin levels in ApoD-KO and control mice. When 222 
compared to control, ApoD-KO mice exhibited similar fasting and non-fasting blood 223 
glucose levels (Fig. 4A). However, non-fasting plasma insulin levels were significantly 224 
elevated in ApoD-KO mice (Fig. 4B). To evaluate the impact of ApoD deficiency on 225 
whole-body glucose disposal rates, glucose tolerance tests were performed. As 226 
shown in Fig. 4C, similar glucose profiles were observed in ApoD-KO and control 227 
mice in response to intraperitoneal glucose infusion. However, ApoD-KO mice show 228 
a trend to increase insulin release during the glucose tolerance test, although this 229 
trend did not achieve statistical significance (data not shown). Based on fasting blood 230 
glucose and plasma insulin levels, we calculated the insulin sensitivity index (ISI). As 231 
shown in Fig. 4D, ApoD-KO mice exhibited similar ISI regardless of age.  However, 232 
ApoD-KO mice at 3 and 21 months of age were associated with increased non-233 
fasting insulin:glucose ratio (Fig. 4E), suggesting that ApoD deficiency is associated 234 
with inappropriate hyperinsulinemia to maintain normoglycemia in non-fasting 235 
conditions. 236 
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Insulin resistance usually precedes the development of glucose intolerance and type 237 
2 diabetes. Before this happens, the pancreas compensates for insulin resistance by 238 
increasing insulin secretion sustaining normoglycemia. Beta-cell compensation can 239 
be accomplishing by increasing beta-cell mass or enhancing cellular secretory 240 
capacity. To investigate why an ApoD deficiency leads to hyperinsulinemia, we 241 
performed a histomorphometric analysis of beta-cell mass in ApoD-KO and control 242 
mice. As shown in Fig 5, pancreatic beta-cell mass (A-D and C), islet volume (B) and 243 
islet number (D) were not significantly different between ApoD-KO and control mice. 244 
These findings suggest that the hyperinsulinemia observed in non-fasting ApoD-KO 245 
mice was not due to beta-cell mass changes or growth, but related to beta-cell 246 
function. 247 
Discussion 248 
In this study, we hypothesized that ApoD deficiency would increase plasma 249 
triglyceride levels and could contribute to the pathogenesis of dyslipidemia. To 250 
contrast this hypothesis, we tested whether mice lacking ApoD gene have elevated 251 
plasma triglycerides levels. We show that ApoD deficiency is associated with 252 
hypertriglyceridemia and decreased LPL protein levels in adipose tissue in non-253 
fasting conditions. Consistently, we previously showed that elevated ApoD 254 
production was associated with increased LPL activity in mice, contributing to 255 
improved postprandial triglyceride clearance [14]. In parallel with these results, 256 
epidemiological studies in African populations have identified three missense 257 
mutations (namely Phe36Val, Tyr108Cys and Thr158Lys) in the ApoD gene 258 
associated with significantly elevated plasma triglyceride levels [16,17]. In addition, 259 
plasma ApoD levels are significantly lower in patients with hyperchylomicronemia 260 
13 
 
[23]. Taken together, these findings demonstrate a role for ApoD in the regulation of 261 
triglyceride metabolism and suggest that ApoD deficiency contributes to the 262 
pathogenesis of dyslipidemia. 263 
Interestingly, hypertriglyceridemia was not accompanied by hepatic accumulation of 264 
triglycerides in non-fasting ApoD-KO mice. At first inspection, the effect of ApoD 265 
deficiency, promoting hypertriglyceridemia and reducing hepatic triglyceride levels, 266 
might seem be contradictory. There are several possible explanations. First, ApoD 267 
deficiency may enhance hepatic VLDL-TG secretion, which would explain the 268 
reduced hepatic TG levels and hypertriglyceridemia in non-fasting conditions. 269 
Second, ApoD deficiency may increase fatty acid oxidation, which would reduce 270 
hepatic triglyceride levels. Third, ApoD deficiency may decrease hepatic “de novo” 271 
fatty acid biosynthesis and/or esterification of exogenous fatty acids. Although the 272 
precise effect of ApoD deficiency on hepatic lipid metabolism needs further 273 
investigation, these possibilities may explain, at least in part, the observed reduced 274 
hepatic triglyceride levels. 275 
ApoD regulation in response to fat load has not been extensively studied. In support 276 
of this notion, we showed that elevated plasma ApoD levels in diet-induced obese 277 
mice was associated with reduced body weight and fat pad mass [14]. Here, we 278 
show an age-dependent effect of ApoD deficiency on food intake and body weight. 279 
Three months old ApoD-KO mice show augmented food intake without an increase in 280 
body weight. Thus, our results are consistent with the hypothesis that ApoD regulates 281 
body weight and energy homeostasis by a potential mechanism that would implicate 282 
enhanced energy expenditure. 283 
In addition to its effect on triglyceride metabolism, young ApoD-KO mice have 284 
reduced non-fasting plasma cholesterol levels compared to WT mice, sustaining the 285 
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concept that ApoD regulates cholesterol metabolism in mice. Supporting such a role, 286 
we have previously shown that hepatic overexpression of ApoD decreased plasma 287 
cholesterol levels in mice [14]. Interestingly, the effect of ApoD deficiency on 288 
cholesterol metabolism was lost with aging. It is plausible that other apolipoproteins 289 
involved in cholesterol regulation such as Apolipoprotein A-I (ApoA-I) compensate for 290 
a deficit in ApoD during aging. Nonetheless, the role of ApoD in the regulation of 291 
cholesterol metabolism remains to be deciphered and further work is warranted. 292 
Also in the context of lipid metabolism, Do Carmo et al. reported that transgenic mice 293 
overexpressing human ApoD show hepatic steatosis with normal plasma triglyceride 294 
levels [15]. The discrepancies in the transgenic mouse phenotypes observed could 295 
be explained by the different methodological approaches used in both studies. First, 296 
two different gain-of-function paradigms (chronic overexpression in transgenic mice 297 
vs. acute overexpression using adenoviral vectors) were used. Second, mouse and 298 
human ApoD cDNA were used to overexpress ApoD in mice. Although human and 299 
mouse ApoD present a high degree of similarity in their sequences, there are some 300 
structural differences that may be of importance to explain the phenotypes. Mouse 301 
ApoD lacks Cys116, a residue involved in the intermolecular covalent cross-link with 302 
Cys6 of Apolipoprotein A-II (ApoA-II) within HDL particles [24]. Finally, ApoD was 303 
overexpressed in different tissues. Do Carmo et al. expressed human ApoD under 304 
the control of neuron specific promoters, while we overexpressed mouse ApoD under 305 
the control of cytomegalovirus (CMV) promoter in liver [15,14]. In summary, further 306 
work using transgenic and knockout tissue-specific mouse models is warranted to 307 
decipher the tissue-specific contribution of ApoD on the regulation of triglyceride 308 
metabolism. 309 
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Finally, the two ApoD homologues in Drosophila, NLaz and GLaz, also regulate total 310 
triglyceride content and neutral fat storage. Total triglyceride content is decreased in 311 
the absence of NLaz and GLaz, whereas overexpression of NLaz increases total 312 
triglyceride content in young flies [11,12]. Curiously, while reduction of neutral fats is 313 
maintained through aging in GLaz mutants, aged flies lacking NLaz in fact 314 
accumulate fat [13]. 315 
Lipocalins are emerging also as significant players in the regulation of systemic 316 
insulin action and glucose metabolism. The Lipocalin retinol-binding protein 4 (RBP4) 317 
and lipocalin-2 (LCN2) are elevated in obese humans correlating with lower insulin 318 
sensitivity [25,26]. Likewise, circulating concentrations of RBP4 and LCN2 are 319 
elevated in obese mice [27,26]. Transgenic overexpression of RBP4 in normal mice 320 
decreases insulin sensitivity, whereas genetic ablation of RBP4 improved insulin 321 
sensitivity [28]. Our findings suggest that the Lipocalin ApoD may play a role in the 322 
regulation of systemic insulin action and glucose metabolism. This hypothesis is 323 
strengthened by epidemiological studies that demonstrate a linkage between TaqI 324 
polymorphism of the ApoD gene and insulin resistance, hyperinsulinemia, obesity 325 
and type 2 diabetes [18,29,19], and that circulating concentrations of ApoD are 326 
reduced in obese mice [14]. In Drosophila, the genetic ablation of NLaz decreased 327 
glycogen and glucose levels, whereas transgenic overexpression increased glucose 328 
levels. Furthermore, NLaz function antagonizes the insulin/IGF signaling pathway 329 
and is critical for the regulation of metabolic adaptations to stress [11]. In rodents, 330 
transgenic overexpression of ApoD in mice is associated with normal non-fasting 331 
blood glucose levels, hyperinsulinemia and glucose intolerance [15]. In this study, we 332 
show that non-fasting ApoD-KO mice exhibit elevated triglyceride levels associated 333 
with hyperinsulinemia and normoglycemia. The higher insulin levels and 334 
16 
 
insulin:glucose ratio in ApoD-KO mice suggest that they are insulin resistant. 335 
Noteworthy, ApoD-KO and WT mice exhibited similar glucose tolerance. Thus, in our 336 
model system a more sophisticated and sensitive technique, such as the 337 
hyperinsulinemic euglycemic glucose clamp, should be used to quantify insulin 338 
sensitivity. Interestingly, hypertriglyceridemia under non-fasting conditions is usually 339 
a characteristic associated with the development of insulin resistance [30].  340 
The fact that hyperinsulinemia in ApoD-KO mice is not accompanied by 341 
hypoglycemia may indicate a pancreatic beta-cell compensatory mechanism to 342 
overcome insulin resistance. However, the observed hyperinsulinemia was not 343 
accompanied by changes in islet morphology, total beta-cell mass, beta-cell volume 344 
or islet number, suggesting that ApoD deficiency does not alter beta-cell growth. 345 
Taken together, these results suggest a role of ApoD in the pathogenesis of insulin 346 
resistance and further research is needed to decipher the potential role of ApoD 347 
deficiency in insulin resistance.  348 
In conclusion, our results suggest that altered plasma ApoD levels link abnormalities 349 
in the regulation of plasma insulin levels and lipoprotein metabolism with the 350 
pathogenesis of dyslipidemia.  351 
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 Figures and legends 464 
Figure 1: Effect of ApoD knockout on lipid metabolism in mice. Blood samples 465 
were collected from male ApoD-KO and WT mice at 3 and 21 months of age in non-466 
fasting or fasting state for the determination of plasma triglycerides (A) and 467 
cholesterol (B). The effect of ApoD depletion on food intake (C) and body weight (D) 468 
were determined at 3 and 21 months of age.  *p<0.05 versus control.  469 
Figure 2: Hepatic triglyceride content. Mice were sacrificed at 21 months of age. 470 
Frozen liver tissues (20 mg) were used to quantify hepatic triglyceride content in 471 
ApoD-KO and WT mice (A) Cryostat sections of livers stained with Oil red O and 472 
counterstained with hematoxylin (B). Calibration bar: 50µm. *p<0.05 versus control.  473 
Figure 3: Effect of ApoD deficiency on LPL levels in adipose tissue. Cell lysates 474 
(20 μg protein) of epididymal fat isolated from WT and ApoD-KO mice were 475 
22 
 
subjected to immunoblot analysis using anti-LPL antibody. After normalizing to  476 
actin, the relative amounts of LPL were compared between WT and ApoD-KO in 477 
mice at 3 months of age. *p<0.05 versus WT.  478 
Figure 4: Effect of ApoD-KO on glucose metabolism in mice. Non-fasting or 479 
fasting blood samples were collected from male ApoD-KO and WT mice for the 480 
determination of plasma glucose (A) and insulin (B). Intraperitoneal glucose tolerance 481 
test (C). Insulin sensitivity indexes (D). Ratio non-fasting insulin:glucose (E). 482 
Figure 5: Quantitative islet histomorphometry of WT and ApoD-KO pancreas. 483 
Insulin staining sections of whole pancreas from WT mice and ApoD-KO mice at 3 484 
and 21 months of age (A). Islet volume (B), histomorphometry of islet mass (C) and 485 
islet number (D). Pancreas weight in the two groups was not significantly different 486 
(data not shown).  Calibration bar: 1 mm. 487 
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